Kymera Therapeutics Inc (KYMR)
43.51
-0.54
(-1.23%)
USD |
NASDAQ |
Nov 21, 16:00
Kymera Therapeutics Enterprise Value: 2.268B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.268B |
| November 20, 2024 | 2.303B |
| November 19, 2024 | 2.225B |
| November 18, 2024 | 2.197B |
| November 15, 2024 | 2.168B |
| November 14, 2024 | 2.426B |
| November 13, 2024 | 2.600B |
| November 12, 2024 | 2.688B |
| November 11, 2024 | 2.807B |
| November 08, 2024 | 2.750B |
| November 07, 2024 | 2.679B |
| November 06, 2024 | 2.655B |
| November 05, 2024 | 2.539B |
| November 04, 2024 | 2.499B |
| November 01, 2024 | 2.460B |
| October 31, 2024 | 2.440B |
| October 30, 2024 | 2.537B |
| October 29, 2024 | 2.590B |
| October 28, 2024 | 2.629B |
| October 25, 2024 | 2.558B |
| October 24, 2024 | 2.605B |
| October 23, 2024 | 2.607B |
| October 22, 2024 | 2.582B |
| October 21, 2024 | 2.465B |
| October 18, 2024 | 2.455B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.445B |
| October 16, 2024 | 2.624B |
| October 15, 2024 | 2.351B |
| October 14, 2024 | 2.432B |
| October 11, 2024 | 2.365B |
| October 10, 2024 | 2.250B |
| October 09, 2024 | 2.256B |
| October 08, 2024 | 2.237B |
| October 07, 2024 | 2.183B |
| October 04, 2024 | 2.238B |
| October 03, 2024 | 2.261B |
| October 02, 2024 | 2.364B |
| October 01, 2024 | 2.465B |
| September 30, 2024 | 2.515B |
| September 27, 2024 | 2.635B |
| September 26, 2024 | 2.685B |
| September 25, 2024 | 2.844B |
| September 24, 2024 | 2.874B |
| September 23, 2024 | 2.718B |
| September 20, 2024 | 2.706B |
| September 19, 2024 | 2.657B |
| September 18, 2024 | 2.489B |
| September 17, 2024 | 2.545B |
| September 16, 2024 | 2.621B |
| September 13, 2024 | 2.466B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
250.87M
Minimum
Oct 27 2023
3.611B
Maximum
Dec 28 2020
1.585B
Average
1.503B
Median
Enterprise Value Benchmarks
| Amgen Inc | 207.22B |
| Voyager Therapeutics Inc | -48.74M |
| Denali Therapeutics Inc | 2.649B |
| Vir Biotechnology Inc | 42.68M |
| Avidity Biosciences Inc | 3.489B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.49M |
| Revenue (Quarterly) | 3.741M |
| Total Expenses (Quarterly) | 75.86M |
| EPS Diluted (Quarterly) | -0.82 |
| Profit Margin (Quarterly) | -1.67K% |
| Earnings Yield | -5.38% |
| Normalized Earnings Yield | -5.218 |